Aficamten is an oral, next-generation cardiac myosin inhibitor currently under development as a potential therapeutic agent for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM).… Read more












Aficamten is an oral, next-generation cardiac myosin inhibitor currently under development as a potential therapeutic agent for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM). This category provides a comprehensive range of high-quality reference materials essential for pharmaceutical development and quality control. Researchers and analytical laboratories utilize these compounds, including the active pharmaceutical ingredient, known process-related impurities, synthetic intermediates, stereoisomers, and stable isotope labelled standards, to facilitate rigorous impurity profiling and method validation. By incorporating these well-characterized reference standards into analytical workflows, laboratories can effectively monitor drug substance stability and ensure adherence to stringent regulatory quality standards. These materials support critical functions such as structural confirmation, quantitative analysis, and the investigation of degradation pathways, providing the necessary tools to maintain compliance with ICH guidelines throughout the drug development lifecycle.